These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9683302)

  • 21. [Irinotecan plus cisplatin for the treatment of advanced non-small cell lung cancer].
    Zhang XR; Zhu YZ; Xiu QY; Han FC; Liu DQ; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):777-9. PubMed ID: 17366795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Nakagawa K; Hirashima T; Tamanoi M; Nitta T; Yana T
    J Clin Oncol; 1994 Jan; 12(1):90-6. PubMed ID: 7505810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly administration of irinotecan (CPT-11) plus cisplatin for non-small cell lung cancer.
    Hino M; Kobayashi K; Yoshimura A; Takeda Y; Hisakatsu S; Yoneda S; Gemma A; Moriya H; Kudoh S;
    Anticancer Res; 2006; 26(6C):4697-703. PubMed ID: 17214329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer.
    Fujita A; Ohkubo T; Hoshino H; Takabatake H; Tagaki S; Sekine K; Abe S
    Br J Cancer; 2003 Sep; 89(6):1008-12. PubMed ID: 12966417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer.
    Takeda Y; Tsuduki E; Izumi S; Hojo M; Kamimura M; Naka G; Kobayashi K; Kudo K
    Br J Cancer; 2005 Dec; 93(12):1341-9. PubMed ID: 16288302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.
    Takeda K; Takifuji N; Uejima H; Yoshimura N; Terakawa K; Negoro S
    Lung Cancer; 2002 Dec; 38(3):303-8. PubMed ID: 12445753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
    Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Matsui K; Kusunoki Y; Takada M; Nakagawa K; Hirashima T; Tsukada H; Yana T
    J Clin Oncol; 1994 Sep; 12(9):1833-41. PubMed ID: 7521905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
    Masuda N; Fukuoka M; Kudoh S; Kusunoki Y; Matsui K; Takifuji N; Nakagawa K; Tamanoi M; Nitta T; Hirashima T
    Br J Cancer; 1993 Oct; 68(4):777-82. PubMed ID: 8398707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group.
    Kudoh S; Fujiwara Y; Takada Y; Yamamoto H; Kinoshita A; Ariyoshi Y; Furuse K; Fukuoka M
    J Clin Oncol; 1998 Mar; 16(3):1068-74. PubMed ID: 9508192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
    Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
    J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
    Oshita F; Yamada K; Saito H; Noda K
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):465-70. PubMed ID: 17960380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical study of irinotecan plus cisplatin for advanced non-small cell lung cancer].
    Han N; Liu ZW; Wang J; Zhang ZM
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Feb; 30(2):349-50. PubMed ID: 20159719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
    Oshita F; Noda K; Nishiwaki Y; Fujita A; Kurita Y; Nakabayashi T; Tobise K; Abe S; Suzuki S; Hayashi I; Kawakami Y; Matsuda T; Tsuchiya S; Takahashi S; Tamura T; Saijo N
    J Clin Oncol; 1997 Jan; 15(1):304-9. PubMed ID: 8996157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of paclitaxel and irinotecan chemotherapy in patients with advanced nonsmall cell lung cancer.
    Oshita F; Saito H; Yamada K; Noda K
    Am J Clin Oncol; 2007 Aug; 30(4):358-60. PubMed ID: 17762435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer.
    Masuda N; Negoro S; Kudoh S; Sugiura T; Nakagawa K; Saka H; Takada M; Niitani H; Fukuoka M
    J Clin Oncol; 2000 Aug; 18(16):2996-3003. PubMed ID: 10944133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer.
    Mori K; Hirose T; Machida S; Yokoyama K; Tominaga K
    Eur J Cancer; 1997 Mar; 33(3):503-5. PubMed ID: 9155540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.